# A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

Study · id `cardio:ct-nct02358096` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02358096](<https://clinicaltrials.gov/study/NCT02358096>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02358096

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

## Technical summary

Registry record NCT02358096. Randomized; triple masking; primary purpose treatment. Start 2015-03-17 (actual); primary completion 2016-10-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 125 participants (enrolled count; ClinicalTrials.gov record NCT02358096, source copy `cardio:ctgov-nct02358096-2024-10-31`, retrieved 2026-10-26)
- Started: 2015-03-17 (actual) (ClinicalTrials.gov record NCT02358096, source copy `cardio:ctgov-nct02358096-2024-10-31`, retrieved 2026-10-26)
- Primary completion: 2016-10-26 (actual) (ClinicalTrials.gov record NCT02358096, source copy `cardio:ctgov-nct02358096-2024-10-31`, retrieved 2026-10-26)
- Completion: 2017-03-15 (actual) (ClinicalTrials.gov record NCT02358096, source copy `cardio:ctgov-nct02358096-2024-10-31`, retrieved 2026-10-26)
- Countries: Czechia; Denmark; Germany; Hungary; Italy; Netherlands; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT02358096, source copy `cardio:ctgov-nct02358096-2024-10-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02358096-2024-10-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Acronym: ALBUM
- Condition: Chronic Kidney Disease
- Condition: Type 2 Diabetes
- Intervention (Drug): ASP8232
- Intervention (Drug): Placebo
- Lead sponsor: Astellas Pharma Europe B.V.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Europe B.V. (`cardio:org-astellas-pharma-europe-b-v`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial (`cardio:pubmed-30413396`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fe0d8b6e14aa407c569f35426714b3eb0f059255437e4219487baa1b2c172acd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
